Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer

NCT02413320 is registered in ClinicalTrials.gov with Priyanka Sharma as lead sponsor.

NCT NCT02413320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer
Lead sponsor
Priyanka Sharma
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
February 1, 2020
Enrollment
101 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer